CanSino Biologics

Company Showcase Sponsor

Founded in China in 2009, CanSino Biologics Inc. (CanSinoBIO) is an industry-leading biopharmaceutical company, dedicated to providing solutions for the prevention and treatment of infectious diseases globally, through research & development, manufacturing and commercialization of innovative high-quality and affordable vaccine products for human use.

CanSinoBIO has been listed on the Main Board of Hong Kong Exchanges and Clearing Limited (HKEX: 6185.HK) and on the Sci-Tech Innovation Board of the Shanghai Stock Exchange (STAR Market, SSE: 688185), making it the first "A+H" dual-listed vaccine company in China. Currently, our launched products include Menhycia® [Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197)], Menphecia® [Groups A and C Meningococcal Polysaccharide Conjugate Vaccine (CRM197)], Convidecia Air® [Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation], Convidecia® [Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)], and Ad5-EBOV [the recombinant Ebola virus vaccine]. At present, the Company is developing and conducting clinical trials of several products including first-in-class vaccines in China and globally innovative vaccines. CanSinoBIO has developed five key platform technologies, including Adenovirus-based viral vector technology, Synthetic biotechnology, Protein structure design and VLP assembly, mRNA and LNP technology as well as Formulation and drug delivery technology. In addition, the Company owns core intellectual property rights and proprietary technologies related to vaccine products. CanSinoBIO has established a rich portfolio of a pipeline products preventing more than ten diseases, including meningitis, pneumonia, pertussis, diphtheria, tetanus, COVID-19, tuberculosis, shingles, Ebola virus disease etc., and is participating in innovative R&D collaboration with multiple research institutions across the world. We have constructed large-scale manufacturing bases in Tianjin and Shanghai, with a floor area of over 100,000 square meters. Both have been designed and constructed, and are operating in accordance with international standards to manufacture multiple novel vaccines. In addition, local fill-and-finish production lines have been set up in Mexico, Pakistan, and Malaysia to establish joint manufacturing. Our well-established marketing and supply system covering Asia, Latin America, Africa, and other regions ensures the rapid distribution of vaccine products worldwide. As a leading enterprise in R&D of innovative vaccine, we are committed to the guard of global public health through the fulfillment of our social and international responsibilities, and the development and supply of high-quality vaccine products, contributing to the global public health programs.

website